We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $866M
1-Year Est. Return 231.68%
This Fund
S&P 500
This Quarter Est. Return
+23.16%
1 Year Est. Return
+231.68%
3 Year Est. Return
+883.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$494M
AUM Growth
+$2.7M
Cap. Flow
-$70.8M
Cap. Flow %
-14.34%
Top 10 Hldgs %
97.17%
Holding
27
New
13
Increased
5
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$28.8M
2
DNLI icon
Denali Therapeutics
DNLI
+$24.9M
3
GHRS icon
GH Research
GHRS
+$24.6M
4
KRRO icon
Korro Bio
KRRO
+$15.8M
5
XNCR icon
Xencor
XNCR
+$10.5M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$144M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$46.5M
3
ADCT icon
ADC Therapeutics
ADCT
+$5.3M
4
IBIO icon
iBio
IBIO
+$874K
5
ALLO icon
Allogene Therapeutics
ALLO
+$677K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
26
DELISTED
Merus
MRUS
– –
-1,534,141
Closed -$144M
PTGX icon
27
Protagonist Therapeutics
PTGX
$9.8B
– –
-700,014
Closed -$46.5M
1
2

Similar funds

OMG
One Madison Group New York $866M AUM 33.81% 1-Year Est. Return
WFAL
Wedbush Fund Advisers, LLC Pasadena, California $863M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCM
Wallace Capital Management Dallas, Texas $871M AUM 13.69% 1-Year Est. Return
BCM
Benchstone Capital Management New York $860M AUM 32.46% 1-Year Est. Return
F1I
Fund 1 Investments Rincon, Puerto Rico $872M AUM 50.95% 1-Year Est. Return
SA
SoftVest Advisors Abilene, Texas $872M AUM 28.76% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $859M AUM 59.08% 1-Year Est. Return

Lynx1 Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Lynx1 Capital Management held 27 positions worth $494M, up 0.55% from $491M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Lynx1 Capital Management withdrew a net $70.8M in Q4 2025, closing 5 positions and reducing 1 holding. Its most notable exit was Merus, an estimated $144M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Lynx1 Capital Management opened a new position in Korro Bio worth $5.43M.

  • Lynx1 Capital Management's largest Q4 2025 buy was Korro Bio: 677,915 shares worth $5.43M.
  • Lynx1 Capital Management added most to Cullinan Oncology in Q4 2025, an estimated $28.8M increase.
  • Lynx1 Capital Management's biggest Q4 2025 reduction was Precision BioSciences, cutting an estimated $276K.
  • Lynx1 Capital Management fully exited Merus in Q4 2025, selling an estimated $144M.
  • Lynx1 Capital Management's ten largest holdings make up 97% of its $494M portfolio in Q4 2025.
  • Lynx1 Capital Management opened 13 new positions and closed 5 in Q4 2025.
  • Lynx1 Capital Management's portfolio value rose 0.55% quarter-over-quarter to $494M.

Based on Lynx1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.